Realm Therapeutics PLC, which last November launched a strategic review, said it plans to sell assets for up to $10m to Urgo US Inc, delist from London's AIM market, while continuing to hold discussions with "interested parties" that might lead to a takeover offer.
Updating on its efforts to seek strategic alternatives after its key asset failed in clincial trials, the Malvern, PA-based biotech...








